Current and emerging evidence-based treatment options in chronic migraine: A narrative review
| Autor: | Agostoni E. C., Barbanti P., Calabresi P., Colombo B., Cortelli P., Frediani F., Geppetti P., Grazzi L., Leone M., Martelletti P., Pini L. A., Prudenzano M. P., Sarchielli P., Tedeschi G., Russo A., The Italian chronic migraine group |
|---|---|
| Přispěvatelé: | Agostoni, E. C., Barbanti, P., Calabresi, P., Colombo, B., Cortelli, P., Frediani, F., Geppetti, P., Grazzi, L., Leone, M., Martelletti, P., Pini, L. A., Prudenzano, M. P., Sarchielli, P., Tedeschi, G., Russo, A., Agostoni E.C., Barbanti P., Calabresi P., Colombo B., Cortelli P., Frediani F., Geppetti P., Grazzi L., Leone M., Martelletti P., Pini L.A., Prudenzano M.P., Sarchielli P., Tedeschi G., Russo A., The Italian chronic migraine group |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Botulinum Toxins
lcsh:Medicine Review Article Anti-CGRP monoclonal antibodies Type A 0302 clinical medicine Chronic Migraine Migraine Disorder Monoclonal Chronic migraine Fremanezumab onabotulinumtoxinA Prophylaxis Topiramate Antibodies Monoclonal Botulinum Toxins Type A Chronic Disease Disabled Persons Humans Migraine Disorders Randomized Controlled Trials as Topic 030212 general & internal medicine Prophylaxi anti-CGRP monoclonal antibodies chronic migraine fremanezumab prophylaxis topiramate antibodies monoclonal botulinum toxins type A chronic disease disabled persons humans migraine disorders randomized controlled Trials as Topic General Medicine Settore MED/26 - NEUROLOGIA Tolerability Disabled Person medicine.drug Human medicine.medical_specialty Evidence-based practice Pain medicine Anti-CGRP monoclonal antibodie Calcitonin gene-related peptide Antibodies 03 medical and health sciences medicine Intensive care medicine business.industry lcsh:R medicine.disease Clinical trial Anesthesiology and Pain Medicine Migraine Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | The Journal of Headache and Pain, Vol 20, Iss 1, Pp 1-9 (2019) The Journal of Headache and Pain |
| Popis: | Background Chronic migraine is a disabling condition that is currently underdiagnosed and undertreated. In this narrative review, we discuss the future of chronic migraine management in relation to recent progress in evidence-based pharmacological treatment. Findings Patients with chronic migraine require prophylactic therapy to reduce the frequency of migraine attacks, but the only currently available evidence-based prophylactic treatment options for chronic migraine are topiramate and onabotulinumtoxinA. Improved prophylactic therapy is needed to reduce the high burden of chronic migraine in Italy. Monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) pathway of migraine pathogenesis have been specifically developed for the prophylactic treatment of chronic migraine. These anti-CGRP/R monoclonal antibodies have demonstrated good efficacy and excellent tolerability in phase II and III clinical trials, and offer new hope to patients who are currently not taking any prophylactic therapy or not benefitting from their current treatment. Conclusions Treatment of chronic migraine is a dynamic and rapidly advancing area of research. New developments in this field have the potential to improve the diagnosis and provide more individualised treatments for this condition. Establishing a culture of prevention is essential for reducing the personal, social and economic burden of chronic migraine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|